Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Public Advisory - Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs

      Français

      News provided by

      Health Canada (HC)

      Nov 06, 2026, 16:40 ET

      Share this article

      Share this article


      OTTAWA, ON, Nov. 6, 2026 /CNW/ --

      Summary

      Unauthorized injectable peptide and non-peptide drugs  - NJ-500mg vials
      Unauthorized injectable peptide and non-peptide drugs - NJ-500mg vials
      Unauthorized injectable peptide and non-peptide drugs  - TR-60mg vials
      Unauthorized injectable peptide and non-peptide drugs - TR-60mg vials
      Unauthorized injectable peptide and non-peptide drugs  - NJ-500mg vials Unauthorized injectable peptide and non-peptide drugs  - TR-60mg vials
      • Product: Unauthorized injectable peptide and non-peptide drugs
      • Issue: Health products – unauthorized products; Contamination
      • What to do: Do not buy or use these products. If you have used them and develop a fever or pain and swelling at the injection site or you feel unwell, seek immediate medical attention. Only buy prescription drugs from licensed pharmacies. Check labels: authorized drugs for sale in Canada have an 8-digit Drug Identification Number (DIN) printed on the label.

      Affected products
      The following products are examples of unauthorized injectable peptide and non-peptide drugs sold online by Shanghai ERP Peptide Biotechnology Co., Ltd.:

      • Human Chorionic Gonadotropin (hCG)
      • MOTS-C
      • NAD+
      • Retatrutide
      • Tesamorelin
      • Tirzepatide

      Issue
      Health Canada is warning consumers not to use or inject unauthorized peptides after lab testing found bacteria in products sold online. Injecting contaminated products can cause serious infections, hospitalization, and in severe cases, life-threatening sepsis. The risk of infection is higher in people with a compromised immune system.

      In Canada, injectable peptides are generally regulated as prescription drugs. Authorized peptide drugs should only be used under the care of a licensed healthcare professional, such as a doctor, to treat specific conditions.

      Health Canada seized and tested unauthorized injectable peptides from Shanghai ERP Peptide Biotechnology Co. Ltd. (ERP Peptide) and found bacteria such as Acinetobacter seifertii, Acinetobacter nosocomialis, and Propionibacterium (Cutibacterium) acnes.

      The Department identified two Canadian online retailers (truenorthbiolabs.ca and bcaxiompeptide.com) selling products from ERP Peptide. Health Canada obtained court-issued entry warrants, seized unauthorized drug products from the two retailers, and – as a result of compliance and enforcement action – the websites are no longer active.

      In total, Health Canada seized over 11,400 vials from ERP Peptide and the two online retailers.

      Selling unauthorized drug products is illegal. Unauthorized products have not been assessed for safety, efficacy, and quality by Health Canada. They have not been demonstrated, through scientific trials, to provide the health benefits that they claim.

      While unauthorized peptides are often promoted for weight loss, muscle growth, anti-aging, or wellness, they may expose you to significant and unpredictable health risks.

      If you inject yourself with an unauthorized peptide drug, you risk hormonal imbalance, mood swings, blood sugar imbalance, liver or kidney damage, blood clots, and growth of cancerous tumours.

      You also risk safety, quality and sterility concerns because there is no way of knowing what is in the product or how it was made. It may:

      • contain too much, too little, or none of the active ingredient
      • contain unlisted, dangerous or unknown ingredients
      • contain contaminants, such as solvents, heavy metals, particles (fibers, glass, plastic), or microbials (bacteria, fungi, endotoxins)
      • be poorly or incorrectly labelled
      • be improperly manufactured, transported or stored
      • lead to allergic reactions, interactions with other medications or other serious complications.

      Health Canada will continue to take enforcement action, including product seizures, testing and disrupting distribution channels, to remove these products from the Canadian market and protect Canadians from preventable harm.

      The Department has requested ERP Peptide to immediately stop selling illegal peptides into Canada and is also working with the Canada Border Services Agency to stop unauthorized shipments from entering the country.

       What you should do

      • If you have used an unauthorized injectable peptide drug and develop symptoms such as redness, swelling, pain at the injection site, fever, chills or you feel unwell, seek medical attention immediately, as these may be signs of a serious infection.
      • Do not buy or use unauthorized drugs. Authorized prescription drugs in Canada have an eight-digit Drug Identification Number (DIN) on the label. You can also check whether a drug has been authorized for sale by searching Health Canada's Drug Product Database.
      • Do not use drugs that are labelled "For Research Use Only – Not for Human Consumption". These are intended for lab use, not human consumption and can be dangerous to your health.
      • Only use prescription drugs prescribed to you under the care of a licensed healthcare professional, and only buy prescription drugs from licensed pharmacies. Be aware of the risks of buying health products online.
      • Dispose of unauthorized peptide drugs by following municipal or regional guidance for chemicals and other hazardous waste or take the product to your local pharmacy for proper disposal.
      • Report any health product-related side effects or complaints to Health Canada. Your reports help identify potentially dangerous products and protect others from harm.
      • Visit Health Canada's Webpage on Peptides to learn more about peptides, their health risks, and steps you can take to protect yourself.

      Related links:

      • Health Canada peptide safety advisories
      • Health Canada information on peptides

      Également disponible en français

      SOURCE Health Canada (HC)

      Media Enquiries: Health Canada, (613) 957-2983, media@hc-sc.gc.ca; Public Enquiries: (613) 957-2991, 1-866 225-0709, info@hc-sc.gc.ca

      Modal title

      Organization Profile

      Health Canada (HC)

        Also from this source

      • Minister Michel to highlight federal budget investments in affordability measures for Canadians

      • Government of Canada releases findings from the National Conversation on Men and Boys' Health

      • Health Canada announces new supports to improve the health of Black Canadians

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.